Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

首页> 外文期刊>The lancet oncology >Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

【24h】

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

机译：患有先前治疗的晚期肝细胞癌的Camrelizumab：多期，开放标签，平行组，随机，第2期试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Blocking the interaction between PD-1 and its ligands is a promising treatment strategy for advanced hepatocellular carcinoma. This study aimed to assess the antitumour activity and safety of the anti-PD-1 inhibitor camrelizumab in pretreated patients with advanced hepatocellular carcinoma.

机译：背景技术阻断PD-1及其配体之间的相互作用是晚期肝细胞癌的有望治疗策略。本研究旨在评估抗PD-1抑制剂Camrelizumab在预处理肝细胞癌预处理患者的抗肿瘤活性和安全性。

著录项

来源
《The lancet oncology》 |2020年第4期|共10页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial [J] . The lancet oncology . 2020,第4期

机译：患有先前治疗的晚期肝细胞癌的Camrelizumab：多期，开放标签，平行组，随机，第2期试验
2. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial [J] . Powles Thomas, Duran Ignacio, van der Heijden Michiel S., The Lancet . 2018,第10122期

机译：紫红素与化疗铂治疗的局部晚期或转移性尿路上皮癌（IMVigor211）：多期，开放标签，第3期随机对照试验
3. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial [J] . Zhu Andrew X., Finn Richard S., Edeline Julien, The lancet oncology . 2018,第7期

机译：Pembrolizumab在先前用Sorafenib治疗的先进肝细胞癌（Keynote-224）：非随机开放标记相2试验
4. Diffusion-weighted MR imaging of advanced hepatocellular carcinoma treated with the oral multikinase inhibitor Sorafenib [C] . C. Schraml, N.F. Schwenzer, H. Rempp, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：口服多激酶抑制剂索拉非尼治疗晚期肝癌的扩散加权MR成像
5. Efficacy and safety of novel collagen conduits filled with collagen filaments to treat patients with peripheral nerve injury: A multicenter, controlled, open-label clinical trial [D] . Saeki Masaomi, 佐伯将臣 2019

机译：充满胶原细丝的新型胶原蛋白导管治疗周围神经损伤患者的疗效和安全性：一项多中心，对照，开放标签的临床试验
6. A multicentre open-label phase-I/randomised phase-II study to evaluate safety pharmacokinetics and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma [O] . D. H. Palmer, Y. T. Ma, M. Peck-Radosavljevic, 2018

机译：一项多中心开放标签I期/随机II期研究评估nintedanib与sorafenib在欧洲晚期肝细胞癌患者中的安全性药代动力学和疗效
7. 983P Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multi-center, phase II trial [O] . J. Xu, J. Shen, S. Gu, 2020

机译：983p Camrelizumab（c）与高级肝细胞癌患者的Apatinib（a）组合（抢救）：开放标签，多中心，II期试验

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

摘要

著录项

相似文献

相关主题

期刊订阅